Emerging strategies for failed percutaneous transluminal coronary angioplasty by Topol, Eric J.
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Eric J. Topol, MD 
S econd only to the problem of restenosis, abrupt closure during percutaneous transluminal coro- nary angioplasty (PTCA) represents a significant 
procedural complication. Of the 200,000 PTCA proce- 
dures performed in the United States in 1987, abrupt 
closure occurred in approximately 10,000 patients-re- 
sulting in triage to emergency coronary artery bypass 
surgery in >6,000 patients and >l,OOO deaths.1-3 
Current approaches to this problem have been limit- 
ed. After intracoronary nitroglycerin is given, intracoro- 
nary or intravenous thrombolytic therapy has been used 
in some cases. However, spasm or thrombosis is very 
rarely the principal cause of abrupt closure. Typically, 
the inciting event is a complex intimal tear. Definite es- 
tablishment of the etiology is confounded by the lack of 
adequate angiographic distinction between thrombus 
and dissection; our methods for decision-making under 
these circumstances are relatively crude. A standard ap- 
proach, which has evolved empirically to “tack up” the 
tear, is the use of prolonged inflations (2 to 5 minutes), 
with a larger balloon dilatation catheter (0.5-mm size 
increase) at low pressure (3 to 5 atmospheres).4 The 
direct intracoronary administration of propranolol or 
fluorinated hydrocarbons has increased our capacity to 
prolong inflations by virtue of a decelerated induction of 
myocardial ischemia. v Combined with these various 
pharmacologic interventions, this overall “t.ack up” 
strategy appears to represent the best current approach 
to the management of abrupt closure. 
In the late 197Os, when a decision was made to send 
the patient for emergency coronary bypass surgery, the 
earliest, most readily available “bail out” strategy was 
to leave or reintroduce the guidewire across the narrow- 
ing.7 In 1985, Hinohara et al8 introduced the autoper- 
fusion catheter, a 3.5Fr catheter with 36 sideholes, 
through which passive aortocoronary blood flow can be 
achieved if positioned across the lesion and if adequate 
systemic blood pressure is present. This catheter may 
serve as a “bridge” to the operating room and has clear- 
ly proved helpful, allowing stabilization of some patients 
and internal mammary artery graft implantation.8,9 
IIowever, use of the autoperfusion catheter can be prob- 
lematic for several reasons: (1) it may not be possible to 
recross the zone of occlusion with a wire, thereby not 
permitting its introduction; (2) in situations with a 
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guidewire secured across the narrowing, in a target ves- 
sel with tortuosity or excessive angulation, it may not be 
possible to pass the catheter distally; (3) adequate sys- 
tolic blood pressure (>80 mm Hg) is required; and (4) 
the catheter is predisposed to thrombotic occlusion, ow- 
ing to relative stagnation of flow and the likelihood of 
preexisting intraluminal fibrin at the time of insertion. 
Thus, the current state of the art of failed coronary an- 
gioplasty management can be summarized as the use of 
empiric strategies that have limited effectiveness for 
sustaining target vessel patency, frequently resulting in 
emergency backup surgical revascularization. 
Quite recently, several innovative methods have been 
developed and preliminary clinical evaluation of most of 
these is currently underway. Although many of these 
methods were originally designed to address restenosis, 
there is more imminent potential for some to deal with 
abrupt closure. These new approaches can be catego- 
rized as either direct or indirect coronary artery meth- 
ods. 
Of the direct approaches, the autoperfusion dilata- 
tion catheterlO is similar to the bail out catheter but the 
balloon allows very prolonged inflation, which anec- 
dotally has reduced the need for emergency bypass sur- 
gery. The endoluminal stent,“J2 which has also been 
developed to reduce restenosis, may find its place in the 
establishment of sustained patency after abrupt closure. 
To date, Sigwart has deployed a stent in 19 cases of 
“refractory” closure, without incident or need for by- 
pass surgery (Ulrich Sigwart, personal communication). 
Laser “welding” of the dissected intimal segment repre- 
sents another alternative that has proved useful in ex- 
perimental studies and has just begun clinical testing for 
abrupt closure.13J4 It is likely that other forms of “pyro- 
plasty” such as electrical or radiofrequency energy 
sources may be equally effective for this purpose. Re- 
cently, the Simpson atherectomy device has been used 
to excise intimal flaps and it too has potential as a direct 
intervention in this setting. 
Besides intraaortic balloon counterpulsation, which 
has frequently been used for intractable abrupt closure, 
2 new indirect percutaneous interventions are being as- 
sessed. The back door perfusion approach is the coro- 
nary sinus, and 2 different methods-synchronized 
retroperfusion or intermittent balloon occlusion-have 
been tested.15J6 It has not yet been established whether 
coronary sinus interventions will restore adequate myo- 
cardial perfusion in patients. A promising indirect inter- 
vention is percutaneous femoral-femoral cardiopulmo- 
nary bypass. If this can be quickly and reliably initiated, 
systemic perfusion is ensured and marked unloading of 
the left ventricle leads to a very low myocardial oxygen 
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consumption.17 Although this technique requires surgi- 
cal femoral vascular repair at the completion of the pro- 
cedure, and 35,000 U of heparin, it is already being 
used prophylactically in more than 30 catheterization 
laboratories in the US (C.R. Bard, Inc., personal com- 
munication). This explosive application of percutaneous 
cardiopulmonary bypass, known as “supported angio- 
plasty”, will be the subject of many presentations at 
next year’s national meetings. 
These new techniques, however, may engender new 
problems. First, the “high risk” patient will remain at 
high risk no matter what new strategy is selected. It will 
therefore be difficult to objectively evaluate the true 
benefit of a particular technique and randomization to a 
control arm is not likely to be feasible in a trial. Second, 
centers without in-house cardiac surgical resources will 
increasingly consider the use of one or more of these 
techniques as a license to practice coronary angioplasty. 
It is necessary to emphasize that none of the strategies 
under development is likely to obviate the absolute re- 
quirement for backup, emergency surgical revascular- 
ization.18 Third, with an array of possible mechanical 
and pharmacologic approaches, a more tailored and 
precise scheme will be necessary. The parallel develop- 
ment of flexible coronary angioscopy, providing direct 
visualization of the diseased segment, is important and 
may make this possible. Without question, concern and 
management of abrupt closure after PTCA have 
plagued patients and operators for many years. With 
the many new and exciting strategies currently under 
development, there is a realistic opportunity to marked- 
ly improve this procedure. 
REFERENCES 
1. Detre K, Holubkov R, Kelsey S, Cowley M, Kent K, Williams D, Myler R, 
Faxon D, Holmes D Jr, Bourassa M, Block P, Gosselin A, Bentivoglio L, Leather- 
man L, Dorms G, King S III, Galichia J, Al-Bassam M, Leon M, Robertson T, 
Passamani E. Percutaneous transluminal coronary angioplasty in 1985-1986 and 
1977-1981. N Engl J Med 1988;318:265-270. 
2. Hospital Statistics. Washington, DC: American Hospital Association, 1987. 
3. Chokshi SK, Meyers S, Abi-Mansour P. Percutaneous transluminal coronary 
angioplasty: ten years’ experience. Prog Cardiouasc Dis 1987;30:147-210. 
4. Stack RS. Technical aspects of emergency percutaneous transluminal coronary 
angioplasty. In: Top01 EJ, ed. Acute Coronary Intervention. New York: Alan R. 
Liss, 1988:61-78. 
5. Cleman M, Jaffee CC, Wohlgelernter D. Prevention of ischemia during percu- 
taneous transluminal coronary angioplasty by transcatheter infusion of oxygenat- 
ed Fluosol DA 2090. Circulation 1986;74:555-562. 
6. Zalewski A, Goldberg S, Dervan JP, Siysh S, Kusiak V, Maroko PR. Myocar- 
dial protection during coronary occlusion in man: beneficial effects of regional 8 
blockade (abstr). JACC 2985;5:445. 
7. Hollman J, Gruentzig AR, Douglas JS Jr, King SB III, Ischinger T, Meier B. 
Acute occlusion after percutaneous transluminal coronary angioplasty-a new 
approach. Circulation 1983,68:725-732. 
8. Hinohara T, Simpson JB, Phillips HR, Stack RS. Transluminal intracoronary 
reperfusion catheter: a device to maintain coronary reperfusion between failed 
coronary angioplasty and emergency coronary bypass surgery. JACC 1988:ll: 
977-982. 
9. Kereiakes DJ, Abbottsmith CW, Callard GM, Flege JB Jr. Emergent internal 
mammary artery grafting following failed percutaneous transluminal coronary 
angioplasty: use of transluminal catheter reperfusion. Am Heart J 1987; 
113:1018-1020. 
10. Turi ZG, Campbell CA, Gottimukkala MV, Kloner RA. Preservation of 
distal coronary perfusion during prolonged balloon inflation with an autoperfusion 
angioplasty catheter. Circulation 1987;75:1273-I 280. 
11. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular 
stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J 
Med 1987;316:701-706. 
12. Schatz RA, Pahnaz JC, Tio FO, Garcia F, Garcia 0, Reuter SR. Ballcon- 
expandable intracoronary stents in the adult dog. Circulation 2987;76:450-457. 
13. Sanborn TA, Haudenschild CC, Garber GR, Ryan TJ, Faxon DP. Angio- 
graphic and histologic consequences of laser thermal angioplasty: comparison with 
balloon angioplasty. Circulation 1987;75:1281-1286. 
14. Spears JR. Percutaneous transluminal coronary angioplasty restenosis: po- 
tential prevention with laser balloon angioplasty. Am J Cardiol 1987,60:6lB- 
648. 
15. Faxon DP, Jacobs AK: Coronary sinus retroperfusion and intermittent occlu- 
sion. In: Top01 EJ, ed. Acute Coronary Intervention. New York: Alan R. Liss, 
1988:255-270. 
16. Gore JM, Weiner BH, Benotti JR, Sloan KM, Okike ON, Cuenoud HF, 
Gaca JM, Alpert JS, Dale” JE. Preliminary experience with synchronized coro- 
nary sinus retroperfusion in humans. Circulation 1986;74:381-388. 
17. Kanter KR, Pennington DG, Vandormael M, Kern MJ, McBride LR, Naun- 
heim KS, Braun P, Taub J, Willman VL. Emergency resuscitation with extracor- 
poreal membrane oxygenation for failed angioplasty. JACC 1988:11:149A. 
18. ACC/AHA Task Force Report. Guidelines for percutaneous transluminal 
coronary angioplasty: a report of the American College of Cardiology/American 
Heart Association Task Force on Assessment of Diagnostic and Therapeutic 
Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coro- 
nary Angioplasty). JACC 1988:12:529-545. 
250 THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 63 
